VPAC1 receptor binding site: Contribution of photoaffinity labeling approach

Neuropeptides

Volumn 44, Issue 2, 2010, Pages 127-132

  Couvineau, A ^a   Ceraudo, E ^a   Tan, Y V ^a   Laburthe, M ^a  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

Class B GPCR; GPCR; Inflammation; Structure activity relationship; VIP; VPAC1 receptor

Indexed keywords

G PROTEIN COUPLED RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; DESENSITIZATION; HOMEOSTASIS; HORMONE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NUCLEAR MAGNETIC RESONANCE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 77049119916     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2009.11.008     Document Type: Article

References (51)

1. Abad C., Martinez C., Juarranz M.G., Arranz A., Leceta J., Delgado M., and Gomariz R.P. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124 (2003) 961-971
2. Abad C., Gomariz R.P., and Waschek J.A. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP. Current Topics in Medicinal Chemistry 6 (2006) 151-163
3. Bourgault S., Vaudry D., Ségalas-Milazzo I., Guilhaudis L., Couvineau A., Laburthe M., Vaudry H., and Fournier A. Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor. Journal of Medicinal Chemistry 52 (2009) 3308-3316
4. Brenneman D.E. Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Peptides 28 (2007) 1720-1766
5. Brubaker P.L. Incretin-based therapies: mimetics versus protease inhibitors. Trends in Endocrinology and Metabolism 18 (2007) 240-245
6. Campbell R.M., Bongers J., and Felix A.M. Rational design, synthesis, and biological evaluation of novel growth hormone releasing factor analogues. Biopolymers 37 (1995) 67-88
7. Ceraudo E., Murail S., Tan Y.V., Lacapère J.J., Neumann J.M., Couvineau A., and Laburthe M. The vasoactive intestinal peptide (VIP) alpha-helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics. Molecular Endocrinology 22 (2008) 147-155
8. Ceraudo E., Tan Y.V., Nicole P., Couvineau A., and Laburthe M. The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor. Journal of Molecular Neuroscience 36 (2008) 245-248
9. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Kuhn P., Weis W.I., Kobilka B.K., and Stevens R.C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318 (2007) 1258-1265
10. Christopoulos A., Christopoulos G., Morfis M., Adawela M., Laburthe M., Couvineau A., Kuwasako K., Tilakaratne N., and Sexton P.M. Novel receptor partners and function of receptor activity-modifying proteins. Journal of Biological Chemistry 278 (2002) 3293-3297
11. Delgado M., Abad C., Martinez C., Leceta J., and Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nature Medicine 7 (2001) 563-568
12. Delgado M., Pozo D., and Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacological Reviews 56 (2004) 249-290
13. Dickson L., and Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacology and Therapeutics 121 (2009) 294-316
14. Dong M., Lam P.C., Pinon D.I., Sexton P.M., Abagyan R., and Miller L.J. Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding. Molecular Pharmacology 74 (2008) 413-422
15. Epstein S. Is cortical bone hip? What determines cortical bone properties?. Bone 41 (2007) S3-8
16. Firestein G.S. VIP: a very important protein in arthritis. Nature Medicine 7 (2001) 537-538
17. Fredrikson R., and Schiöth B. G Protein-coupled receptors in human genome. In: Rognan D. (Ed). Ligand Design for G Protein-coupled receptors (2006), Wiley-VCH, Weinheim 1-27 vol. 30
18. Gilligan P.J., and Li Y.W. Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases. Current Opinion in Drug Discovery and Development 7 (2004) 487-497
19. Gomariz R.P., Martinez C., Abad C., Leceta J., and Delgado M. Immunology of VIP: a review and therapeutical perspectives. Current Pharmaceutical Design 7 (2001) 89-111
20. Gourlet P., De Neef P., Cnudde J., Waelbroeck M., and Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 18 (1997) 1555-1560
21. Gozes I., Divinsky I., Pilzer I., Fridkin M., Brenneman D.E., and Spier A.D. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and celldivision. Journal of Molecular Neuroscience 20 (2003) 315-322
22. Grace C.R., Perrin M.H., DiGruccio M.R., Miller C.L., Rivier J.E., Vale W.W., and Riek R. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America 101 (2004) 12836-12841
23. Harikumar K.G., Morfis M.M., Lisenbee C.S., Sexton P.M., and Miller L.J. Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors. Molecular Pharmacology 69 (2006) 363-373
24. Harikumar K.G., Lam P.C., Dong M., Sexton P.M., Abagyan R., and Miller L.J. Fluorescence resonance energy transfer analysis of secretin docking to its receptor: mapping distances between residues distributed throughout the ligand pharmacophore and distinct receptor residues. Journal of Biological Chemistry 282 (2007) 32834-32843
25. Hoare S.R.J. Mechanism of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors. Drug Discovery Today 10 (2005) 417-427
26. Inzucchi S.E., and McGuire D.K. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 117 (2008) 574-584
27. Jaakola V.P., Griffith M.T., Hanson M.A., Cherezov V., Chien E.Y., Lane J.R., Ijzerman A.P., and Stevens R.C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322 (2008) 1211-1217
28. Jeppesen P.B. Glucagon-like peptide-2: update of the recent clinical trials. Gastroenterology 130 (2006) S127-131
29. Laburthe M., Couvineau A., and Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 28 (2007) 1631-1639
30. Mulder J.E., Kolatkar N.S., and LeBoff M.S. Drug insight: existing and emerging therapies for osteoporosis. Nature Clinical Practice Endocrinology and Metabolism 2 (2006) 670-680
31. Neumann J.M., Couvineau A., Murail S., Lacapère J.J., Jamin N., and Laburthe M. Class-B GPCR activation: is ligand helix-capping the key?. Trends in Biochemical Sciences 33 (2008) 314-319
32. Nicole P., Lins L., Rouyer-Fessard C., Drouot C., Fulcrand P., Thomas A., Couvineau A., Martinez J., Brasseur R., and Laburthe M. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Journal of Biological Chemistry 275 (2000) 24003-24012
33. Onoue S., Misaka S., and Yamada S. Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn-Schmiedebergs Archives of Pharmacology 377 (2008) 579-590
34. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., and Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
35. Parthier C., Kleinschmidt M., Neumann P., Rudolph R., Manhart S., Schlenzig D., Fanghänel J., Rahfeld J.U., Demuth H.U., and Stubbs M.T. Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America 104 (2007) 13942-13947
36. Parthier C., Reedtz-Runge S., Rudolph R., and Stubbs M.T. Passing the baton in class B GPCRs: peptide hormone activation via helix induction?. Trends in Biochemical Sciences 34 (2009) 303-310
37. Perrin M.H., Grace C.R., Digruccio M.R., Fischer W.H., Maji S.K., Cantle J.P., Smith S., Manning G., Vale W.W., and Riek R. Distinct structural and functional roles of conserved residues in the first extracellular domain of receptors for corticotropin-releasing factor and related G-protein-coupled receptors. Journal of Biological Chemistry 282 (2007) 37529-37536
38. Pioszak A.A., and Xu H.E. Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America 105 (2008) 5034-5039
39. Pioszak A.A., Parker N.R., Suino-Powell K., and Xu H.E. Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1. Journal of Biological Chemistry 283 (2008) 32900-32912
40. Runge S., Thøgersen H., Madsen K., Lau J., and Rudolph R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. Journal of Biological Chemistry 283 (2008) 11340-11347
41. Said S.I. Vasoactive intestinal polypeptide (VIP): current status. Peptides 5 (1984) 143-150
42. Scheerer P., Park J.H., Hildebrand P.W., Kim Y.J., Krauss N., Choe H.W., Hofmann K.P., and Ernst O.P. Crystal structure of opsin in its G-protein-interacting conformation. Nature 455 (2008) 497-502
43. Solano R.M., Langer I., Perret J., Vertongen P., Juarranz M.G., Robberecht P., and Waelbroeck M. Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction. Journal of Biological Chemistry 276 (2001) 1084-1088
44. Sun C., Song D., Davis-Taber R.A., Barrett L.W., Scott V.E., Richardson P.L., Pereda-Lopez A., Uchic M.E., Solomon L.R., Lake M.R., Walter K.A., Hajduk P.J., and Olejniczak E.T. Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS. Proceedings of the National Academy of Sciences of the United States of America 104 (2007) 7875-7880
45. Tan Y.V., Couvineau A., Van Rampelbergh J., and Laburthe M. Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor. Journal of Biological Chemistry 278 (2003) 36531-36536
46. 6]-VIP. Journal of Biological Chemistry 279 (2004) 38889-38894
47. Tan Y.V., Couvineau A., Murail S., Ceraudo E., Neumann J.M., Lacapère J.J., and Laburthe M. Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling. Journal of Biological Chemistry 281 (2006) 12792-12798
48. Vaudry D., Falluel-Morel A., Bourgault S., Basille M., Burel D., Wurtz O., Fournier A., Chow B.K., Hashimoto H., Galas L., and Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacological Reviews 61 (2009) 283-357
49. Waelbroeck M., Perret J., Vertongen P., Van Craenenbroeck M., and Robberecht P. Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutations. Biochemical Society Transactions 30 (2002) 437-441
50. Warne T., Serrano-Vega M.J., Baker J.G., Moukhametzianov R., Edwards P.C., Henderson R., Leslie A.G., Tate C.G., and Schertler G.F. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454 (2008) 486-491
51. Yadav M., and Goetzl E.J. Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity. Annals of the New York Academy of Sciences 1144 (2008) 83-89